A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression

A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4088/JCP.V67N0514

P50authorRoy H. PerlisQ88592183
P2093author name stringPaul E. Keck
Daniel Y. Lin
Doug J. Williamson
Mauricio F. Tohen
Michael G. Case
Sara A. Corya
P433issue05
P921main subjectbipolar depressionQ56014658
P304page(s)798-806
P577publication date2006-05-15
P1433published inThe Journal of Clinical PsychiatryQ7743563
P1476titleA 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression
P478volume67

Reverse relations

cites work (P2860)
Q34475987Antipsychotics as antidepressants
Q38003196Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder
Q22241210Bipolar Disorder: An Update
Q38808576Bipolar depression: Managing patients with second generation antipsychotics
Q38109591Clinical issues in use of atypical antipsychotics for depressed patients
Q37737291Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression
Q34515834LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY
Q47623090Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders
Q38297863Managing the side effects associated with commonly used treatments for bipolar depression
Q43211028Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial
Q37256691Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility
Q38072081Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression
Q92001769Recent advances in the biological treatment of mood disorders
Q34218568Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis
Q34616633The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression
Q34649187The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder
Q37852818Treatment strategies for dosing the second generation antipsychotics.
Q37078931Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor

Search more.